Kitabis Pak Named 1 Of The 10 Notable Drug-Device Approvals Of 2014

Kitabis Pak, the first co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS Nebulizer to address cystic fibrosis, was recently listed among ten notable drug-device approvals of 2014, published in the current issue of Drug Development & Delivery.

“Having Kitabis Pak recognized as a notable drug-device approval confirms PARI’s vision to make the prescription process for generic tobramycin and the PARI LC Plus nebulizer more convenient and cost effective for patients,” explainedGeoff Hunziker, the president of PARIUSA. “Since Kitabis Pak is one prescription for both the drug and nebulizer handset, it ensures patients receive the proper delivery device for tobramycin inhalation solution.”

“We have always believed that it is important for patients and healthcare professionals to understand that tobramycin inhalation solution is only approved for use with the nebulizer handset in Kitabis Pak. Being recognized in this category alongside other innovative pharmaceutical companies confirms our approach in setting a new standard of care for nebulized drugs,” explainedJan Zimmermann, Portfolio Manager at PARI USA.

Cystic fibrosis is a life-threatening disease that affects 30,000 patients in the United States alone; the disease is caused by a genetic mutation that leads to poorly hydrated and thickened mucus secretions in the lungs.

Disclaimer:

Lung Disease News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more